Sponsored

Pharma services is creating cross-border opportunities, but GPs should be aware of regulatory and structural issues at play in different jurisdictions, say McDermott Will & Emery’s Kristian Werling and Ellie West.

EY’s Bridget Walsh explains how GPs are refining their value-creation strategies and repositioning themselves towards emerging opportunities in a dislocated market.

Good data management can streamline operations, improve risk management and help firms differentiate themselves from their peers, says Sam Metland, executive vice-president and head of private equity product at Citco UK.

Private funds must rely on fund administrators now more than ever as the outsourcing landscape becomes increasingly fraught, write RSM US’s Christa Clark and Louis Crasto.

Maintaining a high level of transparency within a business represents a value-add proposition in the current PE environment, say Apex Group’s Agnes Mazurek and Georges Archibald.

Firms that integrate advanced technologies into their investment decision-making processes will be better able to compete in the alternatives marketplace, says Alter Domus’s global head of data and analytics products, Gus Harris.

With the industry under increased scrutiny, sponsors must be more active on legislative and regulatory engagement, say Baker McKenzie’s Michael Fieweger and John Fedele.

As the PE investor base becomes increasingly global and diverse, GPs and LPs are harnessing data to mine more investment strategy and portfolio performance insights, says State Street’s Jesse Cole.

In the face of macro headwinds, asset quality and price are more important than ever, says Pomona Capital chief executive Michael Granoff.

The industry has been slow to adopt technology, but democratisation is rapidly driving change and is altering the way the industry operates, says Hamilton Lane’s Erik Hirsch.